{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:09:38Z","timestamp":1787785778801,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-024-11186-5","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T20:49:00Z","timestamp":1732222140000},"page":"3442-3449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relationship between [18F]FDG PET\/CT findings and claudin 18.2 expression in metastatic gastric cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Hongyan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongkui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4813-4262","authenticated-orcid":false,"given":"Hongcheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"11186_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","volume":"388","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 388:2654\u20132664","journal-title":"Lancet"},{"key":"11186_CR2","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3748\/wjg.14.1149","volume":"14","author":"G Maconi","year":"2008","unstructured":"Maconi G, Manes G, Porro GB (2008) Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 14:1149\u20131155","journal-title":"World J Gastroenterol"},{"key":"11186_CR3","first-page":"CD004064","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M et al (2017) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 8:CD004064","journal-title":"Cochrane Database Syst Rev"},{"key":"11186_CR4","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991\u20134997","journal-title":"J Clin Oncol"},{"key":"11186_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108940","volume":"9","author":"R Iacovelli","year":"2014","unstructured":"Iacovelli R, Pietrantonio F, Farcomeni A et al (2014) Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One 9:e108940","journal-title":"PLoS One"},{"key":"11186_CR6","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1093\/annonc\/mdt351","volume":"24","author":"HS Kim","year":"2013","unstructured":"Kim HS, Kim HJ, Kim SY et al (2013) Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol 24:2850\u20132854","journal-title":"Ann Oncol"},{"key":"11186_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1634\/theoncologist.2018-0221","volume":"24","author":"L Fashoyin-Aje","year":"2019","unstructured":"Fashoyin-Aje L, Donoghue M, Chen H et al (2019) FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 24:103\u2013109","journal-title":"Oncologist"},{"key":"11186_CR8","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Fuchs CS, Tabernero J et al (2017) Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 28:2932\u20132942","journal-title":"Ann Oncol"},{"key":"11186_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705999","volume":"12","author":"DK Wang","year":"2021","unstructured":"Wang DK, Zuo Q, He QY, Li B (2021) Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications. Front Immunol 12:705999","journal-title":"Front Immunol"},{"key":"11186_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"11186_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40291-019-00424-y","volume":"23","author":"MA Pereira","year":"2019","unstructured":"Pereira MA, Ramos M, Dias AR et al (2019) Expression profile of markers for targeted therapy in gastric cancer patients: HER-2, microsatellite instability and PD-L1. Mol Diagn Ther 23:761\u2013771","journal-title":"Mol Diagn Ther"},{"key":"11186_CR12","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624\u20137634","journal-title":"Clin Cancer Res"},{"key":"11186_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, Tureci O, Manikhas G et al (2021) FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32:609\u2013619","journal-title":"Ann Oncol"},{"key":"11186_CR14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O Tureci","year":"2019","unstructured":"Tureci O, Sahin U, Schulze-Bergkamen H et al (2019) A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol 30:1487\u20131495","journal-title":"Ann Oncol"},{"key":"11186_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin U, Schuler M, Richly H et al (2018) A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer 100:17\u201326","journal-title":"Eur J Cancer"},{"key":"11186_CR16","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2967\/jnumed.115.160614","volume":"56","author":"K Kawada","year":"2015","unstructured":"Kawada K, Toda K, Nakamoto Y et al (2015) Relationship between [18F]FDG PET\/CT scans and KRAS mutations in metastatic colorectal cancer. J Nucl Med 56:1322\u20131327","journal-title":"J Nucl Med"},{"key":"11186_CR17","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2967\/jnumed.115.171165","volume":"57","author":"R Chen","year":"2016","unstructured":"Chen R, Zhou X, Liu J, Huang G (2016) Relationship between [18F]FDG PET\/CT findings and HER2 expression in gastric cancer. J Nucl Med 57:1040\u20131044","journal-title":"J Nucl Med"},{"key":"11186_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00259-017-3871-5","volume":"45","author":"PS Sung","year":"2018","unstructured":"Sung PS, Park HL, Yang K et al (2018) 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging 45:384\u2013391","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11186_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2967\/jnumed.117.199778","volume":"59","author":"RA Werner","year":"2018","unstructured":"Werner RA, Schmid JS, Higuchi T et al (2018) Predictive value of [18F]FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. J Nucl Med 59:756\u2013761","journal-title":"J Nucl Med"},{"key":"11186_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00259-017-3865-3","volume":"45","author":"M Hatt","year":"2018","unstructured":"Hatt M, Laurent B, Fayad H, Jaouen V, Visvikis D, Le Rest CC (2018) Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method. Eur J Nucl Med Mol Imaging 45:630\u2013641","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11186_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"HJ Im","year":"2018","unstructured":"Im HJ, Bradshaw T, Solaiyappan M, Cho SY (2018) Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging 52:5\u201315","journal-title":"Nucl Med Mol Imaging"},{"key":"11186_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao W, Xing H, Li Y et al (2022) Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res 10:38","journal-title":"Biomark Res"},{"key":"11186_CR23","doi-asserted-by":"publisher","first-page":"1967080","DOI":"10.1080\/21688370.2021.1967080","volume":"10","author":"D Kyuno","year":"2022","unstructured":"Kyuno D, Takasawa A, Takasawa K et al (2022) Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers 10:1967080","journal-title":"Tissue Barriers"},{"key":"11186_CR24","first-page":"3028","volume":"63","author":"T Gu","year":"2022","unstructured":"Gu T, Shi H (2022) Relationship of [18F]FDG PET\/CT parameters and CLDN 18.2 expression status in gastric cancer. J Nucl Med 63:3028\u20133028","journal-title":"J Nucl Med"},{"key":"11186_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, Xu Z, Hu C et al (2023) Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications. Front Oncol 13:1132319","journal-title":"Front Oncol"},{"key":"11186_CR26","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1021\/acsptsci.3c00165","volume":"6","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zhao C, Ding J et al (2023) Screening, construction, and preliminary evaluation of CLDN18.2-specific peptides for noninvasive molecular imaging. ACS Pharmacol Transl Sci 6:1829\u20131840","journal-title":"ACS Pharmacol Transl Sci"},{"key":"11186_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4251\/wjgo.v15.i2.343","volume":"15","author":"E Kayikcioglu","year":"2023","unstructured":"Kayikcioglu E, Yuceer RO, Cetin B, Yuceer K, Karahan N (2023) Prognostic value of claudin 18.2 expression in gastric adenocarcinoma. World J Gastrointest Oncol 15:343\u2013351","journal-title":"World J Gastrointest Oncol"},{"key":"11186_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi C, Chong X, Zhou T et al (2024) Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: a retrospective study. Chin J Cancer Res 36:78\u201389","journal-title":"Chin J Cancer Res"},{"key":"11186_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154699","volume":"248","author":"D Tao","year":"2023","unstructured":"Tao D, Guan B, Li Z, Jiao M, Zhou C, Li H (2023) Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer. Pathol Res Pract 248:154699","journal-title":"Pathol Res Pract"},{"key":"11186_CR30","first-page":"4","volume":"10","author":"MA Pereira","year":"2021","unstructured":"Pereira MA, Ramos M, Dias AR et al (2021) RhoA, claudin 18, and c-MET in gastric cancer: clinicopathological characteristics and prognostic significance in curative resected patients. Med Sci 10:4","journal-title":"Med Sci"},{"key":"11186_CR31","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold A, Daum S, von Winterfeld M et al (2020) Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol 22:2357\u20132363","journal-title":"Clin Transl Oncol"},{"key":"11186_CR32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2013.11.022","volume":"12","author":"KH Jun","year":"2014","unstructured":"Jun KH, Kim JH, Jung JH, Choi HJ, Chin HM (2014) Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int J Surg 12:156\u2013162","journal-title":"Int J Surg"},{"key":"11186_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/path.1922","volume":"208","author":"Y Sanada","year":"2006","unstructured":"Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W (2006) Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol 208:633\u2013642","journal-title":"J Pathol"},{"key":"11186_CR34","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00259-023-06234-z","volume":"50","author":"S Wang","year":"2023","unstructured":"Wang S, Qi C, Ding J et al (2023) First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. Eur J Nucl Med Mol Imaging 50:2802\u20132817","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11186-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-11186-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11186-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:08:02Z","timestamp":1747307282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-11186-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["11186"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-11186-5","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Hongcheng Shi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No study subjects or cohorts have been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}